Skip to contentE
Editas Medicine, Inc.
E
EDITEditas Medicine, Inc. Q3 2018 · 10-Q
Revenue$14.52M$14.52M+131.1% vs Q3 2017 Net Income-$15.24M-$15.24MN/M vs Q3 2017 EPS Diluted-$0.32-$0.32N/M vs Q3 2017 Operating Income-$16,258,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Editas Medicine, Inc. · CIK 1650664 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$8,779,000N/M Margins · derivedOperating margin-112.0%+313.8 pt vs Q3 2017
Net margin-105.0%+318.5 pt vs Q3 2017
ended Sep 30, 2018 · filed Nov 8, 2018 · 39 d after period end